文献速递冠心病外科

多支冠状动脉病变血运重建术后死亡风险评估的解剖与临床风险分层工具

Anatomical and clinical risk stratification tool for mortality risk assessment following revascularization for multivessel coronary artery disease.
PubMed 文献 · J Thorac Cardiovasc Surg · 2021-12-23

该前瞻性注册研究纳入以色列22家医院2013年1月至4月连续收治的1112例多支冠状动脉病变患者,评估SYNTAX评分II对30天和6年死亡率的预测能力。高SYNTAX评分II组30天死亡率2.8%,高于中危组0.6%和低危组0%。SYNTAX评分II每增加1单位,30天死亡比值增加11%(95%CI 1.02-1.22;P=.026)。

要点

  • 高SYNTAX评分II(≥35)患者30天死亡率为2.8%,中危(25-35)为0.6%,低危(<25)为0%。
  • 6年死亡率高危组34.9%,中危组11%,低危组3.8%(log-rank P<.001)。
  • SYNTAX评分II连续变量预测6年死亡的AUC为0.79(95%CI 0.75-0.82)。

核心结论

  • 入院时SYNTAX评分II是短长期死亡率的强效标志物,可能用作多支冠状动脉病变血运重建候选患者的风险分层工具。

研究设计与样本

  • 前瞻性注册研究,纳入以色列全部22家开展冠状动脉造影的医院2013年1月至4月连续收治的1112例多支冠状动脉病变患者。
  • 按SYNTAX评分II分为低危(<25)368例(33%)、中危(25-35)372例(33%)和高危(≥35)372例(33%)。

主要发现

  • 高SYNTAX评分II组30天死亡率2.8%,中危组0.6%,低危组0%(P=.001)。
  • SYNTAX评分II每增加1单位,30天死亡比值增加11%(95%CI 1.02-1.22;P=.026)。
  • 6年死亡率高危组34.9%,中危组11%,低危组3.8%(log-rank P<.001)。
  • 将SYNTAX评分II加入标准预后因素后,预测6年死亡率显著改善40.1%(P<.001)。
  • SYNTAX评分II连续变量预测6年死亡的AUC为0.79(95%CI 0.75-0.82)。

关键数值与推荐

  • SYNTAX评分II低危定义为<25,中危定义为25-35,高危定义为≥35。

临床怎么用

  • 作者认为入院SYNTAX评分II可能用作多支冠状动脉病变血运重建候选患者的风险分层工具。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study aimed to assess the prognostic ability of SYNTAX score II in left main and/or 3-vessel disease patients undergoing revascularization either by coronary artery bypass grafting or percutaneous coronary intervention in a national registry. METHODS: This prospective registry included consecutive patients with multivessel disease enrolled between January and April 2013 from all 22 hospitals in Israel that perform coronary angiography. Of the 1112 study patients, 368 patients (33%) had a low (<25), 372 (33%) had an intermediate (25-35) and 372 patients (33%) a high (≥35) SYNTAX score II. RESULTS: Patients with a high SYNTAX score II had higher 30-day mortality compared with those with an intermediate or low SYNTAX score II (2.8% vs 0.6% vs 0% respectively, P = .001). Each 1-unit increment in SYNTAX score II increased the odds for death at 30 days by 11% (95% CI, 1.02-1.22; P = .026). Six-year mortality was higher among patients with a high compared with an intermediate or low SYNTAX score II (34.9% vs 11% vs 3.8%; log-rank P < .001). By adding a SYNTAX score II to standard prognostic factors, we showed a significant improvement of 40.1% (P < .001) for predicting 6-year mortality. The area under the curve of the SYNTAX score II (continuous) yielded 0.79 (95% CI, 0.75-0.82) in predicting 6-year mortality. CONCLUSIONS: Our findings show that the admission SYNTAX score II is a powerful marker of short- and long-term mortality, and therefore may be used as a risk stratification tool in patients with multivessel coronary artery disease who are candidates for revascularization.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Ram E, Kassif T, Peled Y, et al. Anatomical and clinical risk stratification tool for mortality risk assessment following revascularization for multivessel coronary artery disease. J Thorac Cardiovasc Surg. 2021. PMID: 35031136. doi:10.1016/j.jtcvs.2021.11.090

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。